NCT06241352CompletedPhase 2
Statin Addition to Chemotherapy for Advanced Pancreatic Cancer
A Prospective Clinical Trial of Statin Addition to Chemotherapy for Advanced Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 11 May 2025
Brief summary (registry, in English)
The results of previous studies conducted by our team have revealed that the use of statins can more effectively hinder the growth of drug-resistant pancreatic cancer cells. The primary objective of this study was to investigate the role of statins in treating pancreatic cancer by assessing the safety and therapeutic impact of combining chemotherapy with statins in patients with advanced pancreatic cancer.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 28 Jan 2024
- Start date
- 20 Mar 2024
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Changhai Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06241352
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 42
- From 20 Mar 2024 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously taken lipid-lowering drugs (such as statins, fibrates, ezetimibe, or PCSK9 inhibitors).
Other illness
- Patients with poor condition can not tolerate chemotherapy.
- Impaired organ functions: heart failure (New York Heart Association III- IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure.
- Patients diagnosed with other cancer within 5 years.
Other
- Patients who are taking warfarin, verapamil, clopidogrel, digoxin, amiodarone, etc.
- Patients who are pregnant or breastfeeding.
- Patients enrolled in other clinical trials or incompliant of regular follow up.
- Patients who did not provide an informed consent.
Who the study is looking for
- Age≥18 years old and ≤80 years old.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- Histologically or cytologically confirmed local advanced/metastatic pancreas adenocarcinoma.
- Imaging studies confirmed the diagnosis of locally advanced or metastatic pancreatic cancer patients.
- The patients were in the plateau stage after chemotherapy, as indicated by the CA19-9 values (with CA19-9 negative patients referenced against CEA or CA-125) fluctuating by less than 20% over an interval of more than 3 weeks.
- Life expectancy of greater than 90 days, as judged by the investigator.
- Routine blood test: absolute neutrophil count\>1500/mm3, platelet\>100000/ mm3.
- Normal liver function: serum total bilirubin≤2.0mg/dl, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<3 times of the upper limit of normal value.
- Normal kidney function: serum creatinine\<1.5 times of the upper limit of normal value or creatinine clearance rate\>45ml/min.
- No severe comorbidities.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Changhai Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
Related publications
- A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy.Cell Stem Cell · 2025 · PMID 40812300
This page is information, not medical advice. Discuss any trial with your doctor.